explore -WSS

explore

author：knowledge 2025-10-01 02:12:18 - browse：271

Illustration of doctor with an computer text bubble for a face for a story on Chat GPT and AI – health tech coverage from STAT — Mike Reddy for STAT

Health care companies are racing to incorporate generative AI tools into their product pipelines and IT systems after the technology displayed an ability to perform many tasks faster, cheaper — and sometimes better — than humans.

But the rush to harness the power of so-called large language models, which are trained on vast troves of data, is outpacing efforts to assess their value. AI experts are still trying to understand, and explain, how and why they work better than prior systems, and what blind spots might undermine their usefulness in medicine.

It remains unclear, for example, how well these models will perform, and what privacy and ethical quandaries will arise, when they’re exposed to new types of data, such as genetic sequences, CT scans, and electronic health records. Even knowing exactly how much data must be fed into a model to achieve peak performance on a given task is still largely guesswork.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Victims of gun violence feel impacts long after bullet wound

entertainment

WSS

MoonLake credibility takes another hit with mid

Testing for cancer recurrence creates a new limbo for patients

Cassava reveals details — and problems — with Alzheimer's study

Biotech incubator Curie.Bio graduates its first startup

Victims of gun violence feel impacts long after bullet wound

Will General Catalyst be the first of many hospital takeovers?

entertainment

explore

leisure time

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: XBI biotech index, Akero Therapeutics

23andMe had bad news about my health. I wish a person had delivered it

Meta's Zuckerberg and Chan on track to put $50 billion into science

Cancer drug shortages should be causing more outrage

Paying for Covid pills will soon shift to insurers

What does generative AI mean for health care? We asked experts

Readout Newsletter: What happened with Sarepta's Duchenne data

As demand for Covid shots wanes, Moderna seeks its next success

Traditional Chinese medicine benefits explored in new JAMA study

focus

Medicare solvency divides Republicans at the presidential debate

Biotech incubator Curie.Bio graduates its first startup

The pink breast cancer awareness ribbon needs a redesign

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

MoonLake credibility takes another hit with mid

Free speech concerns arise in wake of journal editor Eisen's firing

hotspot

entertainment

explore

focus